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Background: Iron isomaltoside 1000 is a novel injectable iron compound which offers 
potential advantages in the treatment of subjects with iron-deficiency anemia. We studied the 
pharmacokinetics (PK) of this novel compound in subjects with mild-to-moderate   inflammatory 
bowel disease (IBD).
Methods: This open-label, crossover, single-center trial was conducted in 12 subjects with 
IBD who were allocated to one of the two single intravenous (IV) bolus sequences of iron 
isomaltoside 1000: 100 mg followed by 200 mg, or vice-versa. PK variables were analyzed 
according to a single-compartment model.
Results: The concentration-versus-time relationship for isomaltoside-bound iron (IBI) and total 
iron (TI) showed first-order kinetics with small deviations from dose-linearity. The area under 
the concentration-time curve (AUC) values in h * µg/mL for IBI following 100 mg and 200 mg 
doses were 888 and 2141 respectively, and for TI following 100 mg and 200 mg doses, the AUC 
values were 1010 and 2319 respectively. The corresponding maximum serum concentration 
(Cmax) values in µg/mL were 35.6 and 68.6 for IBI, and 37.3 and 71.1 for TI. The half-life (T½) 
values for IBI and TI were between 20.8–23.5 hours. The apparent volume of distribution (VD) 
ranged from 3.0–3.5 L. Only approximately 1% of the doses administered were excreted in 
the urine. No serious adverse event (SAE) was reported. One subject was withdrawn after the 
100 mg dose due to abdominal pain and flushing.
Conclusion: At the administered doses, iron isomaltoside 1000 showed first-order PK, and 
did not raise safety concerns in patients with IBD. The PK parameters for IBI were close to 
those of TI.
Keywords: inflammatory bowel disease, iron deficiency anemia, iron treatment, iron isomalto-
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Introduction
Iron deficiency anemia is estimated to affect approximately 1.6 billion people   worldwide.1 
It is the most common type of anemia associated with inflammatory bowel disease 
(IBD), which affects approximately 33% of sufferers, particularly in conjunction with 
acute exacerbation of the disease in which bleeding is common. Iron supplementation 
can generally be accomplished by the oral or intravenous (IV) routes; however, in IBD 
patients approximately 90% of the ingested iron is not absorbed, passes the sites of 
intestinal inflammation, and induces local oxidative stress at sites of active inflammation. 
Therefore, the IV route is preferable for iron supplementation in IBD patients.2
Iron isomaltoside 1000 (Monofer®; Pharmacosmos A/S, Holbaek, Denmark) 
is a new chemical structure developed by complexing ferric hydroxide with 
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  isomaltoside 1000. Isomaltoside 1000 is a chemical modi-
fication of   isomaltooligosaccharides with a mean molecular 
weight of 1000 Da, consisting predominantly of 3–5 glucose 
units. In contrast to dextrans, isomaltoside 1000 is linear and 
unbranched, with a low immunological potential – hence, a 
test dose is unnecessary. Iron isomaltoside 1000 contains 
strongly-bound iron within an iron–isomaltoside matrix 
formulation, with little risk of free iron toxicity.3
The primary objective of this trial was to provide 
  pharmacokinetic (PK) data for isomaltoside-bound iron 
(IBI), transferrin-bound iron (TBI), and total iron (TI) in 
subjects with an established diagnosis of IBD after IV 
bolus injection of iron isomaltoside 1000, including the 
potential contribution of urine excretion to the elimination 
of IBI from plasma. The secondary objective was to assess 
the tolerability and safety of iron isomaltoside 1000 in this 
patient population.
Material and methods
Ethics
This study was conducted at a single center in Denmark 
(PhaseOneTrials A/S) in accordance with the Declaration 
of Helsinki and complied with International Conference on 
Harmonization Good Clinical Practice (GCP) and applicable 
regulatory requirements. Prior to commencement, the trial 
protocol and/or other relevant documents were approved by 
the Independent Ethics Committee. Before each subject was 
admitted to the trial, written informed consent was obtained 
from the subject according to Danish regulatory and legal 
requirements.
Trial design, outcomes, and eligibility 
criteria
This was an open-label, crossover, single center, PK trial of 
iron isomaltoside 1000 given as IV bolus doses of 100 mg 
or 200 mg to subjects with IBD.
Inclusion criteria were the following: mild-to-moderate 
IBD (colitis ulcerosa or Crohn’s disease) for at least 
3 months, aged 18–70 years, s-ferritin ,800 µg/L, transferrin 
saturation ,30%, life expectancy beyond 12 months, hemo-
globin (Hb) levels from 8.9–15.3 g/dL in male patients, and 
Hb levels from 8.9–13.7 g/dL in female patients.   Exclusion 
criteria were the following: patients with severe IBD or 
surgery within the last 8 weeks, noniron deficiency anemia, 
iron overload or hemochromatosis or hemosiderosis, previous 
hypersensitivity to iron dextran or monodisaccharide com-
plex, history of multiple allergies, liver cirrhosis or hepatitis, 
acute or chronic infections, rheumatoid arthritis, pregnancy 
or breastfeeding, active bleeding, planned elective surgery 
during the study where significant blood loss was expected, 
and participation in any other clinical study within 3 months 
prior to screening.
The duration of the trial period for each individual subject 
was a maximum of 7 weeks and consisted of nine visits: 
Visit 1 (Day –14 to Day –3, screening), Visit 2 (Day –1, 
randomization; Day 0, baseline and dosing), Visit 3 (24 hours 
postdose), Visit 4 (48 hours postdose), Visit 5 (72 hours 
postdose), followed by a washout period of 28 days, Visit 6 
(Day –1, rehospitalization and Day 0, baseline and dosing), 
Visit 7 (24 hours postdose), Visit 8 (48 hours postdose), 
and Visit 9 (72 hours postdose and treatment termination 
visit). Visit 9 was also to be carried out in withdrawn sub-
jects who had received at least one dose of iron isomaltoside 
1000. Blood samples for PK assessments were drawn at the 
following time points: –30, 0, 5, 10, 15, 30, and 45 minutes, 
and at 1, 1.5, 2, 4, 8, 12, 24, 48, and 72 hours.
Iron isomaltoside 1000 was administered twice to each 
subject as a single IV bolus dose, with a minimum dose 
interval of at least 4 weeks. The first six subjects were 
allocated to group 1 (100 mg/200 mg), and the next six 
subjects were allocated to group 2 (200 mg/100 mg). Iron 
isomaltoside 1000 was administered at an injection rate of 
50 mg iron/min for both doses. For safety reasons,   dosing 
of individual subjects was performed with 30-minute 
intervals.
TI and TBI were measured in plasma and urine, and IBI 
was estimated as the difference between the two. The PK 
parameters were estimated according to a single-  compartment 
model, and included maximum serum concentration (Cmax); 
time to Cmax (Tmax), calculated serum concentration at time 0 
(C0) obtained by back-extrapolation to time 0 of the log-linear 
regression at the 12, 24, 48, and 72 hour sample points, area 
under the serum concentration-time curve from injection to 
last measurable data point (AUC0–end), area under the serum 
concentration-time curve from injection to infinity (AUCinf); 
the elimination constant (Ke) derived from each dosing 
  episode profile by log-linear regression at the 12, 24, 48, and 
72 hour sample point, T½ derived from Ke, and apparent VD 
derived from C0. Urine was sampled accumulatively during 
four time intervals following each dosing event: 0–8, 8–24, 
24–48, and 48–72 hours.
The safety parameters included laboratory tests (hematol-
ogy, biochemistry, and urine analyses), physical examination, 
vital signs (blood pressure, heart rate, and body temperature), 
electrocardiogram (ECG), incidence and severity of adverse 
events (AEs), and adverse drug reactions (ADRs).
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Analytical methods
IBI in human serum was analyzed by Unilabs A/S   (Copenhagen, 
Denmark) (a GCP- and ISO17025-accredited laboratory), 
by means of differentiation method. The TI content was 
determined by Graphite Furnace Atomic Absorption 
Spectrometry (GFAAS) system with Zeeman background 
correction delivered by Varian (now Agilent Technologies, 
Santa Clara, CA). The content of TBI was determined by 
photometry on an automated Advia 1650 Chemistry System 
delivered by Bayer HealthCare (now Siemens Healthcare 
Diagnostics, Munich, Germany). Subtracting the Advia 
result from the GFAAS result yielded the content of IBI, 
assuming that no free iron was present and that amounts of 
ferritin were negligible, so that the only iron forms present 
in plasma were TI, TBI, and IBI. The interassay precision 
(coefficient of variation) of the GFAAS and Advia qual-
ity control samples ranged between 7.6%–10.2% for the 
GFAAS analysis, and between 1.0%–1.1% for the Advia 
analysis. The mean inaccuracy ranged between –1.1%–6.9% 
for the GFAAS analysis and between –1.7% and –3.2% for 
the Advia method. The GFAAS method was used to mea-
sure the total quantity of iron in serum samples after acid 
digestion (65% HNO3) at 115°C followed by the addition of 
Triton-X-100 to obtain a tenfold dilution. A linear calibration 
curve was achieved by the principles of standard addition by 
programming the GFAAS instrument to automatically add 
different concentrations of iron standard to human serum 
containing 43.57 µmol/L. The added iron standard was 
prepared by spiking water with iron isomaltoside 1000 to a 
concentration of 69.56 µmol/L, followed by dilution to the 
added concentration.
The concentration of IBI in urine was also analyzed by 
means of a differentiation method based on the same labo-
ratory methods as for serum iron determination: GFAAS 
for TI, and Advia for TBI. The quality of the method for 
determination of IBI was satisfactory. The interassay pre-
cision (coefficient of variation) of the GFAAS and Advia 
quality control samples ranged between 1.1%–6.9% for the 
GFAAS analysis, and between 0.2%–0.4% for the Advia 
analysis. The mean inaccuracy ranged between –1.8% and 
14.9% for the GFAAS analysis and between 1.4%–4.1% for 
the Advia method.
GFAAS analytical method was used to measure the total 
quantity of iron in urine samples after dilution and addi-
tion of Triton-X-100. The instrument is linear-calibrated, 
using Titrisol-spiked calibrators produced by Unilabs A/S. 
The calibration curve ranged from 0.0–10.1 µmol/L. For 
determination of TBI in urine by ADVIA method, Fe3+ was 
first separated from transferrin under acidic conditions, then 
reduced to Fe2+ with ascorbic acid and finally combined with 
Ferrozine, to give a chromogenic complex which absorbs at 
571/658 nm.
Statistical methods
The crossover design – with a washout period in between 
the two exposures to different doses of iron isomaltoside 
1000 – created a pairing of results that was utilized during 
the analyses. It was not relevant to adjust for   multiplicity. 
A formal sample size calculation was not performed. 
  However, based on data on s-iron concentrations from a 
previous trial (data on file) the coefficient of variation (CV) 
of the mean Cmax was expected to be in the range of 5%–7% 
in 12 subjects. It was assessed that this was a sufficient preci-
sion for the PK endpoints. A sample size of 12 subjects was 
therefore decided.
Primary PK endpoints, AUC0–end and Cmax, were log-
transformed and analyzed in a mixed linear normal model, 
with treatment and visit as fixed effects and subject as random 
effect. The subject factor was included to implement the 
crossover feature of the design.
All primary and secondary endpoints are presented with 
summary statistics. Descriptive statistics for continuous 
variables were presented with N, mean, standard devia-
tion (SD), geometric mean, and CV , where N denotes the 
number of subjects contributing with nonmissing data. 
For discrete variables, descriptive statistics was presented 
with N and percentage of the number of subjects contrib-
uting, with nonmissing data in the various categories of 
the variable.
Adverse events
AEs were recorded at all postbaseline visits, and classified 
according to Medical Dictionary for Regulatory Activities 
(MedDRA) system, version 10.1.4
Results
Patient disposition and demographics
A total of 36 subjects were screened, of which 12 subjects 
with IBD defined by the Lennard-Jones criteria5 were 
included. All subjects were dosed with the two doses (100 mg 
and 200 mg or 200 mg and 100 mg), and completed the study 
except for one subject who only received a single dose of 
100 mg before being withdrawn due to an AE. One subject 
had slightly elevated s-creatinine at inclusion. Baseline 
demographic data are presented in Table 1.
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Pharmacokinetic results
Serum-concentration versus time curves for IBI, TI, and TBI 
with log-transformed concentration values presented as mean ± 
standard error (SE) are shown in Figure 1. The shape of the 
curves for IBI and TI is compatible with first-order PK.
The corresponding descriptive statistics (geometric 
means and CV) are provided in Table 2. A more than 
twofold increase was observed in the mean AUC and Cmax 
for the 200 mg dose compared to the 100 mg dose. The Ke 
was slightly lower, and T½ was slightly longer for 200 mg 
versus 100 mg for IBI and TI (Table 2). This corresponds 
to a deviation from dose-linearity. The apparent VD ranged 
from 3.0–3.5 L.
The concentration-time curve shapes as well as the val-
ues of the mean AUC and Cmax for IBI were close to those 
of TI.
S-transferrin rose slowly, and achieved mean Cmax after 
approximately 5.5 hours, and then declined gradually. The 
ratio between AUC for TBI and TI was 16% for the 100 mg 
dose and 10% for the 200 mg dose.
Comparison of PK estimates between the two crossover 
periods did not reveal any period effect (data not shown).
Table 3 shows excretion of TI in urine. Overall, approxi-
mately 1% of the doses administered were excreted in the 
urine (0.9% after the 100 mg dose and 1.1% following the 
200 mg dose).
Safety results
No SAEs were reported. Nine subjects experienced a total 
of 43 nonserious AEs: 33 were mild, eight were moderate, 
and two were severe (Table 4). Thirty-one events were clas-
sified as related to trial drug (ie, ADRs), and 12 as unrelated. 
One subject was withdrawn from the trial due to an ADR 
after the first dose (100 mg) of iron isomaltoside 1000. 
Among the 11 ADRs experienced by this subject, two were 
graded as severe in intensity (abdominal pain and flushing). 
Despite this, the symptoms were not suggestive of an acute 
anaphylactic reaction; this subject was initially treated with 
antihistamine and glucocorticosteroid to prevent any progres-
sion of the acute reaction and/or a potential delayed allergic 
reaction. The subject was followed up and all ADR symptoms 
were resolved. No other subjects experienced severe ADRs. 
No clinically significant changes in laboratory parameters or 
vital signs were reported. Among all the AEs, three were local 
irritations and two of these were considered ADRs.
Discussion
Anemia is the most common systemic complication of IBD, 
and has considerable impact on quality of life. In a recently-
published guideline on the diagnosis and management of 
anemia and iron deficiency in IBD, authors argued that 
IV iron appears to be more effective, better tolerated, and 
improves the quality of life to a greater extent than oral iron 
Table 1 Baseline characteristics
Treatment: 100 mg + 200 mg Treatment: 200 mg + 100 mg All subjects
N 6 6 12
Age (years) 
  Mean (SD)
 
49.3 (13.7)
 
29.5 (5.8)
 
39.4 (14.4)
Sex, N (%) 
  Women 
  Men
 
3 (50.0) 
3 (50.0)
 
4 (66.7 ) 
2 (33.3 )
 
7 (58.3) 
5 (41.7)
Race, N (%) 
  Caucasian
 
6 (100.0)
 
6 (100.0)
 
12 (100.0)
Height (m) 
  Mean (SD)
 
1.74 (0.1)
 
1.72 (0.1)
 
1.73 (0.1)
Weight at baseline (kg) 
  Mean (SD)
 
79.0 (19.3)
 
65.0 (13.4)
 
72.0 (17.4)
Body mass index at baseline (kg/m2) 
  Mean (SD)
 
25.9 (6.1)
 
21.8 (1.8)
 
23.8 (4.8)
Hemoglobin (mmol/L) 
  Mean (SD)
 
8.1 (0.4)
 
8.0 (0.9)
 
8.1 (0.7)
S-ferritin (µg/L) 
  Mean (SD)
 
73.2 (53.1)
 
65.8 (48.2)
 
69.8 (48.5)
Transferrin saturation (%) 
  Mean (SD)
 
18.6 (6.7)
 
12.7 (7.8)
 
15.4 (7.6)
C-reactive protein (mg/L) 
  Mean (SD)
 
3.5 (3.8)
 
7.0 (8.1)
 
5.2 (6.3)
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supplements.2 The PK data obtained from this study can be 
considered valuable in this patient cohort, who may benefit 
from iron isomaltoside 1000.
The concentrations of IBI in plasma and urine were 
derived from concentrations of TI and TBI, assuming 
that no free iron was present and that the amount of fer-
ritin was negligible so that the only iron forms present in 
plasma were TI, TBI, and IBI. This so-called differentia-
tion method was also used in the studies of PK of ferric 
gluconate,6,7 while PK of ferumoxytol8,9 was based on direct 
Figure 1 Iron concentration versus time in plasma (mean ± SE) (log-scale). (A) 0–72 hours (reduced number of initial time points). (B) -0 to 4 hours.
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iron-hydroxide sucrose complex12 both of which saw a fast 
initial drop during the first 4–6 hours, followed by a slower 
elimination rate.
For both IBI and TI, a more than twofold increase was 
observed in the mean AUC and Cmax for the 200 mg dose, 
compared to the 100 mg dose, which was a deviation from 
dose-linearity and correlates with PK of ferumoxytol,8 which 
likely represents the capacity-limited elimination from 
plasma to the reticuloendothelial system (RES) described 
previously.13 The VD based on apparent initial concentration 
ranged from 3.0–3.5 L. This corresponds roughly to the 
plasma volume (normally 40–50 mL/kg), and is comparable 
to the other IV iron preparations except ferric gluconate, for 
which a VD at steady-state reached 6.7 L in one study.6 This 
indicates that practically all IBI is contained in plasma before 
being eliminated by RES.
The PK analysis was done assuming a one-compart-
ment model with first-order PK, the model also used for 
a single-dose study of ferumoxytol.8 Other authors used 
a two-compartment model for PK of iron-carbohydrate 
complex; for repeated-dose ferumoxytol9 and for ferric 
gluconate,7 however, both one- and two-compartment 
methods described the data accurately. For carbohydrate-
bound iron, a one-compartment model makes sense from 
the physiological viewpoint. According to the literature, IV 
iron compounds are eliminated from plasma by the RES, 
which splits the compound into iron and carbohydrate.11,13 
Once sequestered by RES, the complex cannot be restored 
in the circulation, thus the RES is not a “compartment” 
as there is no return of the complex from RES to plasma. 
Rather, RES should be considered as the elimination system 
for the complex.
However, two compartments may be considered for TI: 
plasma (central compartment) and RES (peripheral com-
partment) (Figure 2). RES is also an elimination pathway 
Table 2 Geometric mean (CV in %) for PK parameters of isomaltoside-bound iron, total iron, and transferrin-bound iron
Endpoint Isomaltoside-bound iron Total iron Transferrin-bound iron
Treatment Treatment Treatment
100 mg 200 mg 100 mg 200 mg 100 mg 200 mg
AUC0–end (h * µg/mL) 809 (24) 1885 (20) 894 (21) 2017 (19) 82.6 (19) 129 (15)
AUC0–inf (h * µg/mL) 888 (22) 2141 (23) 1010 (19) 2319 (21) 163 (67) 228 (51)
Cmax (µg/mL) 35.6 (39) 68.6 (26) 37.3 (38) 71.1 (26) 2.1 (30) 3.0 (16)
Tmax (minutes) 37 (109) 27 (104) 38 (151) 28 (112) 218 (166) 221 (191)
C0 (µg/mL) 28.3 (32) 64.5 (29) 28.9 (32) 66.7 (28) 1.7 (36) 2.9 (37)
Ke (1/hour) 0.033 (12) 0.031 (24) 0.030 (15) 0.029 (23) 0.011 (85) 0.013 (87)
T1/2 (hour) 20.8 (12) 22.5 (24) 23.2 (15) 23.5 (23) 62.2 (85) 53.9 (87)
VD based on C0 (L) 3.5 (32) 3.1 (29) 3.5 (32) 3.0 (28) 60.6 (36) 68.3 (37)
measurement of the drug-bound iron by MR spectrometry, 
and PK of iron-hydroxide sucrose complex were based on 
the measurement of TI. The PK parameters for IBI were 
close to that of TI, which implies that TI may be a good 
surrogate for IBI. Recent in vitro studies document that 
the tightly-bound iron isomaltoside 1000 matrix formula-
tion contains a very low level of free iron.3,10 The fact that 
low-molecular-weight iron dextran had higher free iron 
in these experiments highlights the differences between 
these compounds.3,10
For both TI and IBI, the shape of the log-transformed 
concentration-versus-time curves were compatible with first 
order PK, which is consistent with the PK of iron-dextran 
for iron doses up to 500 mg,11 and with ferumoxytol for 
iron doses up to 4 mg/kg after a single IV dose.8 This did 
not appear to be the case for ferric-gluconate6,7 nor for 
Table 3 Total iron in urine (µg/mL)
Time Treatment
100 mg 200 mg
Baselinea 
  No 
  Mean (SD)
 
12 
0.212 (0.0)
 
11 
0.212 (0.0)
0–8 hours 
  No 
  Mean (SD)
 
11 
1.252 (0.586)
 
11 
2.191 (0.654)
8–24 hours 
  No 
  Mean (SD)
 
12 
0.252 (0.050)
 
11 
0.453 (0.154)
24–48 hours 
  No 
  Mean (SD)
 
11 
0.213 (0.003)
 
11 
0.218 (0.019)
48–72 hoursa 
  No 
  Mean (SD)
 
12 
0.212 (0.0)
 
11 
0.212 (0.0)
Notes: aConcentrations below lower limit of quantification (LLOQ) were set to 
LLOQ. This occured for all measured urine iron concentrations at baseline and the 
72 hour sample point. Hence, the means for these time points are identical and equal 
to LLOQ with SD = 0.
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for TI, which is then either bound to intracellular storage 
proteins (eg, in the liver), or transported to bone marrow 
for hematopoiesis. Other elimination methods include urine 
excretion, and loss due to blood sampling. Although iron 
contained in storage proteins and iron incorporated into 
erythrocytes returns to plasma, this process is not part of the 
model since it is unlikely to occur before practically all iron 
has been eliminated from plasma, following a single admin-
istration of iron isomaltoside 1000. TBI is not considered 
a separate compartment for TI, since it is contained in the 
central compartment (plasma). Based on the ratio between 
AUCs for TBI and TI, 10%–16% of iron administered as 
IBI returns to plasma from the RES compartment, under the 
assumption that all measured TBI originates from the iron 
isomaltoside complex. Despite the theoretical presence of 
the RES compartment, the shape of the concentration-time 
curve for TI suggests that plasma and RES behave as a single 
compartment for the purposes of PK.
The elimination T½ for IBI and TI for the 100 mg dose 
was 20.8 and 23.2 hours respectively, which is slightly 
shorter than T½ for iron dextran, which was approximately 
30 hours,11 slightly longer than for ferumoxytol, which was 
approximately 16 hours for a 250 mg dose8, and significantly 
longer than the T½ for iron-sucrose complex,12 ferric carboxy-
maltose, and ferric gluconate.6,7,14 The T½ should be taken into 
account when selecting the dose frequency. The observed 
mean Tmax values for IBI and TI ranged from 27–38 minutes. 
By comparison, Tmax values for TI after bolus injection of 
ferric carboxymaltose were 16 minutes after a bolus injection 
and 20, 60, and 72 minutes following a 15-minute infusion 
of 500, 800, and 1000 mg respectively.15
Urine excretion was negligible (Table 3). The average 
amount excreted was 0.9% of the injected dose following 
administration of the100 mg dose (range: 0.6%–1.1%) and 
following the 200 mg dose the urine iron excretion was 
1.1% of the dose administered (range: 0.7%–1.4%). This 
indicates that renal elimination of iron associated with IV 
administration of iron isomaltoside 1000 is negligible, and 
this has two clinical implications: (1) that iron administered 
as iron isomaltoside 1000 is almost entirely confined to the 
organism and can be used for hematopoiesis; and (2) no 
impact of renal failure on the elimination of TI is expected. 
By comparison, the calculated proportion of ferric gluconate 
excreted in the urine was 2.4% and 2.3% after IV infusions 
of 62.5 mg and 125 mg, respectively.6 For iron sucrose, the 
urine excretion of iron is more important and corresponds 
to 5% during the first 4 hours postdose.12
The iron loss due to plasma sampling was not taken into 
account. No allergic reactions were seen in the current trial. 
One subject experienced multiple AEs (11 ADRs reported 
on the 100 mg dose) and was withdrawn after the first dose. 
Despite this, the symptoms were not suggestive of an acute 
anaphylactic reaction; the patient was initially treated with 
antihistamine and glucocorticosteroid to prevent any progress 
in the acute reaction and/or a potential delayed allergic reac-
tion. The subject was followed up and all ADR symptoms 
were resolved.
There was no correlation between dosage and the number 
of ADRs or their severity. From the reported ADRs and their 
severity (excluding the withdrawn subject) it was not possible 
to correlate ADRs to Cmax or AUC from the different dosages. 
Table 4 Adverse events according to MedDRA preferred term 
and by severity
Na (%)a Ea
Exposed subjects 12
Total 9 75 43
Mild 9 75 33
  Abdominal pain upper 2 17 2
  Abdominal tenderness 1 8 1
  Back pain 1 8 1
  Chest discomfort 1 8 1
  Constipation 2 17 2
  Cystitis 1 8 1
  Dizziness 2 17 3
  Dry mouth 1 8 1
  Dysgeusia 1 8 1
  Feeling cold 1 8 1
  Flushing 1 8 1
  Headache 1 8 1
  Hordeolum 1 8 1
  Injection site irritation 2 17 2
  Injection site pain 1 8 1
  Nasopharyngitis 1 8 1
  Nausea 3 25 3
  Sensory disturbance 1 8 1
  Rash 1 8 2
  Sensation of foreign body 1 8 1
  Tachycardia 3 25 4
Moderate 3 25 8
  Abdominal discomfort 1 8 1
  Crohn’s diseaseb 1 8 1
  Dizziness 1 8 1
  Flushing 1 8 2
  Nausea 2 17 2
  Sensory disturbance 1 8 1
Severe 1 8 2
  Abdominal pain upper 1 8 1
  Flushing 1 8 1
Notes: aN: Number of subjects with event, % = percentage of exposed with event, 
E = number of events; bThe lower level term was “Crohn’s disease aggravated”.
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There were too few reported ADRs, and from the review in 
the investigator’s brochure there was no obvious relationship 
between either of the kinetic factors mentioned.
Overall, iron isomaltoside 1000 (100 mg and 200 mg) 
given as an IV injection not exceeding 50 mg iron/minute 
showed, as expected, a first-order kinetic profile for both IBI 
and TI, and was also shown to be safe in the administered 
doses in this IBD-diagnosed patient group. The compound has 
been given at single doses from 100 mg to as high as 1800 mg 
to patients with either chronic kidney disease or chronic heart 
failure suffering from iron-deficiency anemia.16,17 Based upon 
the current study, TI can be used as surrogate for IBI in future 
PK studies with such high doses of iron isomaltoside 1000.
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